FDA/CDC

FDA recalls kratom products for salmonella contamination


 

The Food and Drug Administration on April 3 recalled all products containing kratom manufactured by Triangle Pharmanaturals LLC, after a number of supplements tested positive for salmonella.

The FDA advises consumers to get rid of products including Raw Form Organics Maeng Da Kratom Emerald Green, Raw Form Organics Maeng Da Kratom Ivory White, and Raw Form Organics Maeng Da Kratom Ruby Red.

Evidence of the contamination was found after two samples were collected from a retail store in Oregon by the Oregon Public Health Division and tested positive for salmonella.

ThorPorre/commons.wikimedia.org

The Mitragyna Speciosa tree, from which the drug kratom is produced.

The recall was ordered after Triangle Pharmanaturals did not comply with a March 30 formal request from the FDA to voluntarily recall their products.

“This action is based on the imminent health risk posed by the contamination of this product with salmonella, and the refusal of this company to voluntarily act to protect its customers and issue a recall, despite our repeated requests and actions,” said FDA Commissioner Scott Gottlieb, M.D., said in a statement. “The action today is based on the risks posed by the contamination of this particular product with a potentially dangerous pathogen.”

At press time, Triangle Pharmanaturals did not respond to a request for comment.

Pages

Recommended Reading

Serotonin syndrome warnings magnify its rare probability
MDedge Psychiatry
Serotonin syndrome risk with triptans and antidepressants ‘very low’
MDedge Psychiatry
Opioid deaths in the ED increase nationally
MDedge Psychiatry
Nonopioid analgesics have no major disadvantages vs. opioids for chronic pain
MDedge Psychiatry
Opioid prescriptions got shorter in 2017
MDedge Psychiatry
The case for being open-minded about medical marijuana
MDedge Psychiatry
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Psychiatry
Is kratom the answer to the opioid crisis?
MDedge Psychiatry
FDA advisors recommend lofexidine for opioid withdrawal
MDedge Psychiatry
How precision psychiatry helped my patient; Ketamine: The next ‘opioid crisis’?
MDedge Psychiatry